These results revealed the regulatory mechanism of developing an anti-ferroptosis defense by upregulating SLC7A11 expression as a key consequence of IDO1 activity in GBM cells, thereby reducing cell death and promoting tumor progression. This evidence concerns the gene IDO1 and glioblastoma.